| Biologic Therapy |
1 |
1 |
| Biosimilars |
0 |
0.99 |
| Blood |
0 |
0.49 |
| Blood Transfusion |
0 |
0.4 |
| End-Stage Renal Disease |
0 |
0.33 |
| Monoclonal Antibody |
0 |
0.3 |
| Atypical Hemolytic Uremic Syndrome |
0 |
0.98 |
| Intravenous |
0 |
0.27 |
| Renal Failure |
0 |
0.24 |
| Hemolytic Uremic Syndrome |
0 |
0.2 |
| Paroxysmal Nocturnal Hemoglobinuria |
0 |
0.2 |
| Meningococcal Disease |
0 |
0.12 |
| Muscular Atrophy |
0 |
0.12 |
| Myasthenia Gravis |
0 |
0.12 |
| Patient Safety |
0 |
0.12 |
| Revenue and Practice Management |
0 |
0.12 |
| Europe |
0 |
0.1 |
| Food and Drug Administration (FDA) |
0 |
0.1 |
| Hemolysis |
0 |
0.1 |
| Rare Diseases |
0 |
0.1 |
| Risk Evaluation and Mitigation Strategies |
0 |
0.1 |
| Transfusion |
0 |
0.1 |